KALV
KalVista Pharmaceuticals, Inc.15.90
-1.00-5.92%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
803.69MP/E (TTM)
-Basic EPS (TTM)
-3.94Dividend Yield
0%Recent Filings
8-K
EKTERLY hits $49M 2025 revenue
KalVista reported preliminary unaudited global net product revenue of ~$35M for Q4 and $49M for full-year 2025 from EKTERLY launch since July. US saw 1,318 patient start forms and 580 unique prescribers; refills now drive most Q4 sales. Latin America partnership with Multicare adds a third deal in 10 months. Pediatric NDA due Q3 2026. Figures preliminary, pending audit.
10-Q
Q3 FY2025 results
KalVista kicked off EKTERLY sales with $13.7M product revenue in Q3 ended September 30, 2025—its first ever, versus zero a year ago—yet posted a $46.1M operating loss, up 6% y/y from $43.5M (derived), as SG&A quadrupled to $46.5M on commercial ramp-up while R&D halved to $12.0M. Net loss hit $49.5M or $(0.92) per share on 53.9M diluted shares, wider than $39.1M or $(0.84) last year, with the gap to operating loss driven by $4.8M interest expense on new royalty and convertible notes obligations. Cash swelled to $243.5M plus $65.7M marketable securities, bolstered by $139M notes proceeds (3.25% due 2031) and $21M royalty drawdown, funding ops at least 12 more months. Customer concentration runs high. EKTERLY approvals rolled in from FDA July 2025 through Australia October. Competition shadows HAE on-demand turf.
8-K
EKTERLY revenue hits $13.7M
KalVista reported $13.7 million in net product revenue from EKTERLY's US launch in Q3 ended September 30, 2025, with 937 patient start forms through October signaling rapid HAE adoption. Germany launch kicked off with initial orders; cash hit $309 million to fund through profitability. EKTERLY expands globally.
8-K
KalVista names COO Arif
KalVista Pharmaceuticals appointed Bilal Arif as COO effective October 6, 2025, bringing 25+ years from Sarepta and Shire to bolster operations amid EKTERLY's global launch. Terms include $520,000 base, 40% target bonus, and options for 100,000 shares vesting over four years. New leadership sharpens commercial edge. Standard severance applies.
8-K
Sensenig joins KalVista Board
KalVista appointed Bethany Sensenig to its Board and Audit Committee on October 1, 2025, bringing 20+ years of finance and commercial expertise from Radius Health and Biogen. Nancy Stuart shifts from Audit to Compensation Committee. She gets options for 45,000 shares upfront. Strong governance boost amid EKTERLY launch.
ATXS
Astria Therapeutics, Inc.
12.87-0.05
CALC
CalciMedica, Inc.
5.22+0.59
ELVN
Enliven Therapeutics, Inc.
16.91-0.26
KALA
KALA BIO, Inc.
0.56-0.05
KLRS
Kalaris Therapeutics, Inc.
8.66+0.16
KRRO
Korro Bio, Inc.
8.22+0.26
LSTA
Lisata Therapeutics, Inc.
2.05+0.01
LXRX
Lexicon Pharmaceuticals, Inc.
1.20-0.03
VIRX
Viracta Therapeutics, Inc.
0.01+0.00
VRTX
Vertex Pharmaceuticals Incorpor
454.96-0.75